Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) announced that the Company will be presenting at the Rodman & Renshaw Annual Global Investment Conference being held at the Waldorf Astoria in New York City from September 9th through 11th, 2012. Leslie J. Browne, Ph.D., President and CEO of Senesco, will deliver the Company’s corporate presentation, and Dr. Browne will also discuss the Company’s clinical program on Monday, September 10th, at 2:00 p.m. (Eastern Time) in the Palm room.
Senesco recently reported on the results of the first cohort of a Phase 1b/2a clinical study of SNS01-T, the Company’s lead therapeutic candidate for the treatment of multiple myeloma. SNS01-T was safe and well tolerated and met the criteria for Stable Disease in 2 of the 3 evaluable patients that comprised cohort 1.
The Company’s webcast presentation may be viewed at: http://www.wsw.com/webcast/rrshq22/snt The webcast will be available for 90 days following the presentation.
About SNS01-TSNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, and the Mary Babb Randolph Cancer Center in Morgantown, WV. http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1 About Multiple Myeloma Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies, in which abnormal cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal blood cells. Senesco was previously granted orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of multiple myeloma.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV